Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
about
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerWhen Prostate Cancer Circulates in the BloodstreamPersistent androgen receptor addiction in castration-resistant prostate cancerNovel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerAndrogen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Detection fidelity of AR mutations in plasma derived cell-free DNACell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.Expression Profiling of Castanea Genes during Resistant and Susceptible Interactions with the Oomycete Pathogen Phytophthora cinnamomi Reveal Possible Mechanisms of ImmunityNovel agents for castration-resistant prostate cancer: Early experience and beyond.Genomic predictors for treatment of late stage prostate cancer.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.Liquid biopsy: a step forward towards precision medicine in urologic malignancies.Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate CancerTargeting the androgen receptor in triple-negative breast cancer: current perspectives.Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.Serum and Plasma Copy Number Detection Using Real-time PCR.Cell-Free DNA Integrity Analysis in Urine Samples.Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.Plasma AR and abiraterone-resistant prostate cancer.Neueste technologische Entwicklungen für die Analyse von zirkulierender Tumor-DNAPlasma androgen receptor and serum chromogranin A in advanced prostate cancer
P2860
Q26751237-62EA7864-738C-47BF-BC80-BCE65C7181F5Q26768470-2EB22815-569C-4334-8090-F5D694E0252FQ26777163-1417132C-A97F-4D8E-ACFB-7A6893A558EEQ28067556-58093F85-7CF5-4BB9-A6D9-6443F329889FQ36398998-180A4887-8EC0-453A-A493-C99A507EF5F2Q36407003-77D4C399-6FF6-44D7-BE86-7AD7A4D586B4Q37134564-428BAD55-6243-45F0-8183-CB335DA608D1Q37335554-0A539C6B-11B6-49BA-9B37-D77F5B096ECEQ37462283-D81142DE-36BB-418F-90EE-6F9A45F7A349Q37716596-A9BD2B86-DBD2-49FB-823D-B7002F8BEACCQ37725496-15EF79B7-2DB9-4D2E-BCB7-61D37F8CB6C4Q37747143-D18E4AC9-F6F5-49D8-BECF-AAA6EA9A1015Q38574684-749C672E-E1CF-4348-84C6-4E729F7966C8Q38794112-F795B99E-170D-415D-959E-DC052254B5D5Q38804089-FEA26A10-A517-4441-97C2-123D39743AC9Q38827251-70D968AF-A117-44D4-825D-1A051DEEDB1DQ38827364-D34F72F5-16B3-4F76-A14D-3B77393FEBF2Q38994718-A3D874A7-C5BA-48E5-9434-DE95F266B682Q39085996-3D84856B-4681-459C-ABC1-0AF9AA77DCDAQ39243268-6298E245-47DD-4778-875F-0AE4194449FAQ40374954-815A3287-3CD7-4982-A6FC-E9E70B15D426Q42174990-05848D32-3678-4931-92BF-D40A5BC8ABE6Q42364449-1E8DC004-096B-41D2-9BB0-6AE1F1A97A30Q43169980-21E316AA-0D98-4256-9187-1B6ADA29F1FFQ44453209-AF2934B6-DBB0-465C-88F9-685BCB191580Q45988129-287DA1CD-8A35-4A78-A98C-EB80A842F6DBQ47645575-82819399-85C5-4ED8-943A-0B5BB1528FE3Q48510469-F495E8EC-1B9C-4302-987F-5F12AEF28340Q50935891-38356444-7892-429A-A256-DC31753A3EC2Q51465026-184BA4F0-1B99-4C23-AD3B-C3C9ABF654E9Q52637922-BBCE8305-C6F7-4870-B9F3-6CDB5AF3E917Q53810482-7471E20A-D260-4B12-84FE-255DFA61CD5AQ57636579-C186256B-32A9-448C-9C89-E77642E2EEB9Q58603582-A4FD9D99-9D2D-4937-A18B-857D0185765F
P2860
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Circulating cell-free AR and C ...... ents treated with abiraterone.
@ast
Circulating cell-free AR and C ...... ents treated with abiraterone.
@en
type
label
Circulating cell-free AR and C ...... ents treated with abiraterone.
@ast
Circulating cell-free AR and C ...... ents treated with abiraterone.
@en
prefLabel
Circulating cell-free AR and C ...... ents treated with abiraterone.
@ast
Circulating cell-free AR and C ...... ents treated with abiraterone.
@en
P2093
P2860
P50
P356
P1476
Circulating cell-free AR and C ...... ients treated with abiraterone
@en
P2093
E Carretta
S L Burgio
U De Giorgi
P2860
P2888
P304
P356
10.1038/BJC.2015.128
P407
P577
2015-04-21T00:00:00Z